Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65. https://doi.org/10.1056/NEJMoa021993.

Article  CAS  PubMed  Google Scholar 

Libby P. The changing landscape of atherosclerosis. Nat. 2021;592:524–33. https://doi.org/10.1038/s41586-021-03392-8.

Article  CAS  Google Scholar 

Martínez GJ, Robertson S, Barraclough J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4:e002128. https://doi.org/10.1161/jaha.115.002128.

Article  PubMed  PubMed Central  Google Scholar 

Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circ. 2012;126:2739–48. https://doi.org/10.1161/circulationaha.112.122556.

Article  CAS  Google Scholar 

Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505. https://doi.org/10.1056/NEJMoa1912388.

Article  CAS  PubMed  Google Scholar 

Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with chronic coronary disease. N Engl J Med. 2020;383:1838–47. https://doi.org/10.1056/NEJMoa2021372.

Article  CAS  PubMed  Google Scholar 

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489.

Article  CAS  PubMed  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664.

Article  CAS  PubMed  Google Scholar 

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107. https://doi.org/10.1056/NEJMoa1801174.

Article  CAS  PubMed  Google Scholar 

Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84. https://doi.org/10.7326/m14-2385.

Article  PubMed  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.

Article  PubMed  PubMed Central  Google Scholar 

Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013;13:35. https://doi.org/10.1186/1471-2288-13-35.

Article  PubMed  PubMed Central  Google Scholar 

Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58. https://doi.org/10.1186/s12874-015-0060-8.

Article  PubMed  PubMed Central  Google Scholar 

Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–10. https://doi.org/10.1016/j.jacc.2012.10.027.

Article  CAS  PubMed  Google Scholar 

Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142:1890–900. https://doi.org/10.1161/circulationaha.120.050771.

Article  PubMed  Google Scholar 

Akrami M, Izadpanah P, Bazrafshan M, et al. Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovasc Disord. 2021;21:583. https://doi.org/10.1186/s12872-021-02393-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ako J, Hibi K, Tsujita K, et al. Effect of Alirocumab on coronary atheroma volume in Japanese Patients with acute coronary syndrome- the ODYSSEY J-IVUS trial. Circ J. 2019;83:2025–33. https://doi.org/10.1253/circj.CJ-19-0412.

Article  CAS  PubMed  Google Scholar 

Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. Jama. 2022;327:1771–81. https://doi.org/10.1001/jama.2022.5218.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–19. https://doi.org/10.1056/NEJMoa1912387.

Article  CAS  PubMed  Google Scholar 

Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–39. https://doi.org/10.1056/NEJMoa1701488.

Article  CAS  PubMed  Google Scholar 

Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017;38:2264–76. https://doi.org/10.1093/eurheartj/ehx162.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495–507. https://doi.org/10.1016/j.jacc.2015.05.065.

Article  PubMed  Google Scholar 

Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statin: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186–94. https://doi.org/10.1093/eurheartj/ehv028.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–32. https://doi.org/10.1056/NEJMoa1803917.

Article  CAS  PubMed  Google Scholar 

Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statin on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. Jama. 2019;322:1780–8. https://doi.org/10.1001/jama.2019.16585.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: a new target for prevention. Stroke. 2021;52:2697–706. https://doi.org/10.1161/strokeaha.121.034388.

Article  PubMed  Google Scholar 

Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214–24. https://doi.org/10.1016/s0140-6736(12)60110-x.

Article  PubMed  Google Scholar 

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72. https://doi.org/10.1093/eurheartj/ehx144.